NeuraLight

Findings of a new study from University of Cambridge on the effect of #atomoxetine, a noradrenaline reuptake inhibitor, on the #eyemovements patients with #Parkinson's disease, suggest that the #oculomotor system can support the assessment of #cognitive effects without limb-motor confounds on task performance. https://t.ly/MjDCc

Results of a new review paper from University of Oxford highlight some consistent differences in #eyemovements between people with #Parkinson's disease and healthy aging in naturalistic scenarios https://t.ly/4ED9i

A new published paper from Universidad Nacional Autónoma de México on patients with early #Huntington's disease #HD who revealed abnormalities of #eyemovements, suggestive the involvement of brain stem deficits https://t.ly/QbsXn

In these days, as the 2024 #NobelPrize announcements are made by The Royal Swedish Academy of Sciences and the Karolinska Institutet, this is a good opportunity to express our gratitude to the distinguished members of NeuraLight advisory board, #NobelPrize laureates Prof. Thomas C. Südhof, MD, PhD, and Prof. Alvin Roth, PhD for their exceptional contribution to the development of #science, #medicine and #healthcare. Thank you! https://t.ly/e5464

Over the last decades, a large evidence-based knowledge was gathered on the role of #eyemovements as a window to the #brain in #CNS diseases. Check our new NeuraLight website to find out more on the science behind out technology https://t.ly/-PRk8

#Eyemovements have been known for decades as a relevant assessment tool for #Alzheimer's disease. This new study examined changes in pupillary responses as potential #biomarkers in patients with mild cognitive impairment #MCI https://t.ly/kPsbw

Today, October 10th, is #WorldMentalHealthDay. At NeuraLight, we leverage the use #eyemovements as a biomarker for #MentalHealth diseases. See this review on different oculometric characteristics in #schizophrenia. https://t.ly/2Oeg4

Check out our cool new website, with a list of all of NeuraLight peer-reviewed publications, presenting the results of using our #eyemovements platform in clinical practice #CNS diseases #Parkinson's #ALS #MS https://t.ly/mLsWu

The NeuraLight team attended the congress of the International Parkinson and Movement Disorder Society, where our partners from Rush University Medical Center and Beilinson - Rabin Medical Center presented their work on using our software-based #eyemovements platform in the assessment of patients with #Parkinson's #MDScongress

The NeuraLight team attended the ECTRIMS conference, where our joint work with the Copenhagen University Hospital Rigshospitalet and the Danish #Multiplesclerosis registry was presented! #ECTRIMS2024